Background: We analysed the survival of patients after glioma diagnosis in relation to the use of wireless phones. Methods: All cases diagnosed between 1997 and 2003 with a malignant brain tumour (n = 1,251) in our case-control studies were included and followed from the date of diagnosis to the date of death or until May 30, 2012. Results: For glioma, the use of wireless phones (mobile and cordless phones) gave a hazard ratio (HR) = 1.1 (95% confidence interval, CI = 0.9–1.2), with >10-year latency HR = 1.2 (95% CI = 1.002–1.5, p trend = 0.02). For astrocytoma grade I-II (low-grade), the results were, HR = 0.5 (95% CI = 0.3–0.9) and for astrocytoma grade IV (glioblastoma), HR = 1.1 (95% CI = 0.95–1.4), with >10 year latency HR = 1.3 (95% CI = 1.03–1.7). In the highest tertile (>426 h) of cumulative use, HR = 1.2 (95% CI = 0.95–1.5) was found for glioblastoma. The results were similar for mobile and cordless phones. Conclusions: Decreased survival of glioma cases with long-term and high cumulative use of wireless phones was found. A survival disadvantage for astrocytoma grade IV, but a survival benefit for astrocytoma grade I-II was observed which could be due to exposure-related tumour symptoms leading to earlier diagnosis and surgery in that patient group.

1.
Hardell L, Carlberg M, Hansson Mild K: Pooled analysis of two case-control studies on use of cellular and cordless telephones and the risk for malignant brain tumours diagnosed in 1997–2003. Int Arch Occup Environ Health 2006;79:630–639.
2.
Hardell L, Carlberg M, Hansson Mild K: Pooled analysis of two case-control studies on the use of cellular and cordless telephones and the risk of benign brain tumours diagnosed during 1997–2003. Int J Oncol 2006;28:509–518.
3.
Hardell L, Carlberg M, Hansson Mild K: Pooled analysis of case-control studies on malignant brain tumours and the use of mobile and cordless phones including living and deceased subjects. Int J Oncol 2011;38:1465–1474.
4.
Hardell L, Carlberg M, Hansson Mild K: Case-control study on cellular and cordless telephones and the risk for acoustic neuroma or meningioma in patients diagnosed 2000–2003. Neuroepidemiology 2005;25:120–128.
5.
Baan R, Grosse Y, Lauby-Secretan B, El Ghissassi F, et al: Carcinogenicity of radiofrequency electromagnetic fields. Lancet Oncol 2011;12:624–626.
6.
Lai H, Singh NP: Melatonin and a spin-trap compound blocked radiofrequency radiation-induced DNA strand breaks in rat brain cells. Bioelectromagnetics 1997:18:446–454.
7.
Phillips JL, Singh NP, Lai H: Electromagnetic fields and DNA damage. Pathophysiology 2009;16:79–88.
8.
Hardell L, Carlberg M, Hansson Mild K: Mobile phone use and the risk for malignant brain tumors: a case-control study on deceased cases and controls. Neuroepidemiology 2010;35:109–114.
9.
Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109.
10.
Vertosick FT Jr, Selker RG, Arena VC: Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography. Review. Neurosurgery 1991;4:496–501.
11.
Ohgaki H, Kleihues P: Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. Review. J Neuropathol Exp Neurol 2005;64:479–489.
12.
Ohgaki H, Dessen P, Jourde B, et al: Genetic pathways of glioblastoma: a population-based study. Cancer Res 2004;64:6892–6899.
13.
Watanabe K, Sato K, Biernat W, et al: Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 1997;3:523–530.
14.
Ohgaki H, Kleihues P: Epidemiology and etiology of gliomas. Review. Acta Neuropathol 2005;109:93–108.
15.
Kundi M: Essential problems in the interpretation of epidemiologic evidence for an association between mobile phone use and brain tumours. C R Phys 2010;11:556–563.
16.
Ohgaki H, Kleihues P: Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 2012;28:177–183.
17.
Festa M, Del Valle L, Khalili K, et al: BAG3 protein is overexpressed in human glioblastoma and is a potential target to therapy. Am J Pathol 2011;178:2504–2512.
18.
Costa FP, de Oliveira AC, Meirelles R, et al: Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields. Br J Cancer 2011;105:640–648.
19.
Zimmerman JW, Pennison MJ, Brezovich I, et al: Cancer cell proliferation is inhibited by specific modulation frequencies. Br J Cancer 2012;106:307–313.
20.
IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Non-Ionizing Radiation. Part 1. Static and extremely low-frequency electric and magnetic fields. Lyon, IARC, 2002.
21.
Lai H, Singh NP: Magnetic-field-induced DNA strand breaks in brain cells of the rat. Environ Health Perspect 2004;112:687–694.
22.
Foliart DE, Pollock BH, Mezei G, et al: Magnetic field exposure and long-term survival among children with leukaemia. Br J Cancer 2006;94:161–164.
23.
Svendsen AL, Weikopf T, Kaatsch P, Schüz J: Exposure to magnetic fields and survival after diagnosis of childhood leukemia: a German cohort study. Cancer Epidemiol Biomarkers Prev 2007;16:1167–1171.
24.
Linde T, Hansson Mild K: Measurement of low frequency magnetic fields from digital cellular telephones. Bioelectromagnetics 1997;18:184–186.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.